INNOVATIVE KEYS TO
HEALTH AND WELLBEING

THE INNOVATIVE KEYS
TO HEALTH AND WELLBEING



PROVIDING VALUE-​​ADDED INNOVATIONS

Innokeys is a Singapore based biotechnology company founded in 2012 with the aim of developing and commercializing innovations that contribute to fulfilling the unmet medical needs in oncology.



Innokeys is currently leading the development activities of nimotuzumab, an anti-EGFR monoclonal antibody treatment for cancers with epithelial origin. Nimotuzumab is invented and developed in Cuba by the Center of Molecular Immunology (CIM) and is already approved in more than 30 countries world-wide.



CORE VALUES

MAKING INNOVATION ACCESSIBLE

Innokeys activities span from identification, acquisition, development and commercialization of suitable innovations.

READMORE >>

NEWS